About Event
Welcome to the Inaugural Tumour Models Summit Nordics!
Dedicated to Improving Target Selection, Facilitating Biomarker Discovery & Achieving Clinical Translatability
Preclinical oncology research continues to face significant hurdles, with over 80% of phase III clinical trials failing to yield effective treatments. To bridge the gap, the development of accurate models to reflect cellular and molecular diversity is essential for improving drug discovery and therapeutic testing.
The inaugural Tumour Models Nordics Summit provided the opportunity to join a dynamic community of 70+ industry leaders from Preclinical, Translational, Discovery, Toxicity, and Biology development teams. This event was dedicated to fostering discussions on best practices for optimizing and implementing oncology models with greater translatability to clinical outcomes.
What You Missed
The 2025 summit addressed the latest advancements in:
  Accelerating drug development pipelines by validating next-generation cancer models tailored for precision oncology
  Harnessing patient-derived xenografts (PDX) and personalised systems to improve translational accuracy & treatment outcomes
  Discovering and implement cutting-edge biomarker strategies to enhance predictive power and treatment selection
  Integrating multi-omics technologies to maximise model relevance and unlock actionable insights for cancer therapies
Industry pioneers, including Anocca, Roche, Adcendo, Sprint Biosciences and Biovent, shared their expertise in transforming cancer research and therapeutics development.
Why Did Delegates Attend?
Complimentary Access for Drug Developers & Academics
Pioneering Approaches in Tumour Models
Opportunity to Expand Your Network
Attendees enjoyed exclusive, free attendance to advance their translational research and accelerate pipeline development. This offer was specifically designed for professionals in the Nordic region to connect with leading tumour model providers, ensuring they could identify the most effective platforms for their studies.
Attendees gained valuable insights from case studies on:
- 3D tissue models that replicate the complexity of human cancers
- Using omics data to identify novel therapeutics targets.
- Development predictive models to overcome challenges in drug tolerability
Attendees took part in tailored networking opportunities, including a speed networking session, to exchange challenges, share insights, and inspire solutions that advance clinical confident and relevance in tumour models research.
Who Attended?
View the blind attendee list to see the full list of companies and various job titles that were in attendance...
What Experts Have Said
"The Tumour Models Summit Nordics provides actionable insights to enhance preclinical model translatability, refine workflows, and build strategic partnerships to drive advancements in precision oncology and increase clinical confidence"
- Chief Scientific Officer | CuraCell